{"groups":[{"description":"Eligible participants with TCR-MM, who were B-cell maturation antigen (BCMA) naïve, who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) Cohort A were included.","id":"FG000","title":"C1071003 Cohort A"},{"description":"Eligible participants with TCR-MM who initiated SOC treatment and were identified from TM-MM database in real world setting under routine clinical practice outside of clinical trials were included. This arm served as external control arm.","id":"FG001","title":"RWD: TM-MM Database"},{"description":"Eligible participants with TCR-MM who initiated SOC treatment and were identified from Flatiron Health database in real world setting under routine clinical practice outside of clinical trials were included. This arm served as external control arm.","id":"FG002","title":"RWD: Flatiron Health Database"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"277"},{"groupId":"FG002","numSubjects":"238"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"277"},{"groupId":"FG002","numSubjects":"238"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Available data from eligible participants was evaluated in approximately 9 months (study start date: 01-September-2023 to study completion date: 31-May-2024) of this retrospective, observational study as per its objectives.","recruitmentDetails":"Data of eligible participants with triple class refractory (TCR) multiple myeloma (MM) treated with elranatamab \\[data utilized form clinical trial C1071003\\] or standard of care treatment (SOC) \\[data utilized from real world data (RWD) sources Therapy Monitor MM (TM-MM) Germany dataset and the Flatiron Health database\\] was collected."}